BIND RUS, Russian pharmaceutical resident company of the Biomedical Cluster of Skolkovo Foundation, opened new R&D center on the territory of Technopark «Slava» on 6 February
The company is a wholly owned subsidiary of BIND Therapeutics Inc, located in Cambridge, USA, which is responsible for developing nanomedicine technology platforms for medicine targeted transport into body organs and tissues. Along with other twenty biomedical startups this American company originated in the lab under the direction of Professor Robert S. Langer.
«This laboratory of biotechnological engineering is the biggest in the whole world. Bob Langer himself has more than a thousand patents», - said Elmira Safarova, General Director of BIND Biosciences RUS, at the press conference devoted to the R&D center Opening in Technopark «Slava». In 2013 Robert Langer and his counterpart Omid Farokhzad became RUSNANOPRIZE laureats, the award set up by RUSNANO. Awarding the laureates took place within the «Open Innovations» forum in Moscow.
BIND RUS was established in 2011 as a result of investment agreement with RUSNANO. Scott Minick, BIND Therapeutics President and Chief Executive Officer, claimed BIND RUS to be the first R&D unit of western pharmaceutical companies in Russia.
Together with its parent company BIND RUS develops and commercializes preparations of targeted and programmable therapeutic actions based on the patented Medicinal Nanoengineering platform. Speaking about the platform Ms Safarova said that BIND Therapeutics design special polymeric nanoparticles called Accurins. They concentrate a therapeutic payload at the site of disease and provide for its controlled and timely release. Such mechanism enables them to enhance their efficiency while minimizing adverse effects on healthy tissues.
Anatoly Chubais, chairman of the Executive Board of RUSNANO, stressed the importance of the platform-based technology. In his opinion, similar approach can be used not only in oncology, but also for other targeted therapeutic delivery of approved medicines into diseased cells and tissues.
According to Ms Safarova one of the main aimes of BIND RUS is to transfer up-to-date technologies from America to Russia. For this purpose several Russian scientists from the company did an internship in Cambridge, USA, in 2012. Futhermore, new R&D center in Technopark «Slava» is equipped with the most state-of-the-art equipment as in its parent company in accordance with global standards and international practices. All this make it perfectly clear that the company will succeed in its research projects and new discoveries